Glenmark Pharmaceuticals shares rallied 3.6 percent intraday on July 9 after the company received approval from US health regulator for anti-anginal drug.
The US Food and Drug Administration granted its approval for Ranolazine extended-release tablets, which will be available in 500 mg and 1,000 mg strengths.
Ranolazine is a generic version of Ranexa extended-release tablets of Gilead Sciences, Inc. The drug improves blood flow to help the heart work more efficiently.
For more information on Equity Market News Call us ✆ – 0731-6642300 or Visit http://www.epicresearch.co
Connect with our social media sites
Follow @Epic_Research
Connect with our social media sites
Follow @Epic_Research
No comments:
Post a Comment